Advances in the discovery and development of melanoma drug therapies

References

• Key Statistics for Melanoma Skin Cancer. American Cancer Society. [cited 2021 Apr 21]. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html (2020).
   Google Scholar
• Leonardi GC, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018;52(4):1071–1080.
   PubMed Web of Science ®Google Scholar
• Rastrelli M, Tropea S, Rossi C, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. Int J Exp Clin Pathophysiol Drug Res. 2014;28:1005–1011.
   Google Scholar
• Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol. 2014;6:31–44.
   Google Scholar
• Stages of melanoma skin cancer - Canadian Cancer Society. [cited 2021 Apr 21]. Available from: https://www.cancer.ca/en/cancer-information/cancer-type/skin-melanoma/staging/?region=on.
   Google Scholar
• Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366–1379.
   PubMed Web of Science ®Google Scholar
• Lopez-Bergami P, Fitchman B, Ronai Z. Understanding signaling cascades in melanoma. Photochem Photobiol. 2008;84(2):289–306.
   PubMed Web of Science ®Google Scholar
• Melanoma. Understanding relevant molecular pathways as well as available and emerging therapies. AJMC. 2015. Available from: https://www.ajmc.com/view/ace0032_sep15_melanomace_mckibbin_s224
   Google Scholar
• Domingues B, Lopes J, Soares P, et al. Melanoma treatment in review. ImmunoTargets Ther. 2018;7:35–49.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009; 23(6):488–96.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Schwartz GK. Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol. 2013;31(3):290–297.
   PubMed Web of Science ®Google Scholar
• Coit DG, Thompson JA, Albertini MR et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2019;17(4):367–402
   Google Scholar
• Pretto F, Elia G, Castioni N, et al. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother. 2014 Sep;63(9):901–910.
   PubMed Web of Science ®Google Scholar
• Croce L, Coperchini F, Magri F, et al. The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget. 2019;10(61):6623–6640.
   PubMedGoogle Scholar
• Khaddour K, Kurn H, Zito PM. Vemurafenib.StatPearls: Treasure Island (FL); 2020.
   Google Scholar
• Kim A, Cohen MS. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Expert Opin Drug Discov. 2016;11(9):907–916.
   PubMed Web of Science ®Google Scholar
• McGuinn D, Aziz RM. Pharmacology and toxicology NDA review and evaluation: zelboraf (vemurafenib). Silver Spring, MD. 2011.
   Google Scholar
• Niezgoda A, Niezgoda P, Czajkowski R. Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy. In: BioMed research international. 2015. Vol. 2015. Article ID. 851387: 1-16.
   Google Scholar
• Putman AH, Weis SL. Pharmacology/Toxicology NDA review and evaluation tafinlar (dabrafenib). Silver Springs, MD: Food and Drug Administration. 2013.
   Google Scholar
• Sanchez JN, Wang T, Cohen MS. BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers. Drugs. 2018;78(5):549–566.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–1327.
   PubMed Web of Science ®Google Scholar
• Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018;30(2):125–133.
   PubMed Web of Science ®Google Scholar
• Multi-disciplinary review and evaluation NDA210496 braftovi (encorafenib). Silver Springs, MD: Food and Drug Administration. 2017
   Google Scholar
• Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122–136.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM,  Simeone E, Festino L, et al. MEK inhibitors in the treatment of metastatic melanoma and solid tumors. Am J Clin Dermatol. 2017;18(6):745–754.
   PubMed Web of Science ®Google Scholar
• Shirley M. Encorafenib and binimetinib: first global approvals. Drugs. 2018;78(12):1277–1284.
   PubMed Web of Science ®Google Scholar
• Gilmartin AG, Bleam MR, Groy A. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favourable pharmacokinetic properties for sustained in vivo pathway inhibition. Cancer Ther Preclin. 2011;17(5):989–1000.
   PubMed Web of Science ®Google Scholar
• Hoffner MSN. ANP-BC, AOCNP, B. & Benchich, MSN, NP-C, AOCNP, K. Trametinib: a Targeted Therapy in Metastatic Melanoma. J Adv Pract Oncol. 2018;9:741.
   PubMedGoogle Scholar
• Pharmacology/Toxicology NDA review and evaluation trametinib. Silver Springs, MD: Food and Drug Administration. 2012
   Google Scholar
• Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016 Jan;8(1):48–56.
   PubMed Web of Science ®Google Scholar
• Cobimetinib. Cobimetinib for metastatic melanoma. Aust Prescr. 2017;40(1):30–31.
   PubMedGoogle Scholar
• Weis SL, Goheer A. Pharmacology/Toxicology NDA review and evaluation cotellic (cobimetinib). Food and Drug Administration, Silver Springs, MD. 2015: 1–88
   Google Scholar
• Khasar S, Weiss S, Thompson M, Pazdur R. NDA multi-disciplinary review and evaluation mektovi (binimetinib). Food and Drug Administration, Silver Springs, MD. 2017:1–246.
   Google Scholar
• Sun J, Zager JS, Eroglu Z. Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. Onco Targets Ther. 2018 Dec 14;11:9081–9089
   Google Scholar
• Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463-482.
   Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma. N Engl J Med. 2014;371(20):1867–1876.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–615.
   PubMed Web of Science ®Google Scholar
• Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–1823.
   PubMed Web of Science ®Google Scholar
• Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–636.
   PubMed Web of Science ®Google Scholar
• Ascierto P, Dummer R, Gogas H, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020Feb;126:33–44.
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Eigentler T, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019 Published online 2019 May 23;4(3):e000491.
   PubMed Web of Science ®Google Scholar
• Hagen B, Trinh VA. Managing side effects of vemurafenib therapy for advanced melanoma. J Adv Pract Oncol. 2014 Nov-Dec;5(6):400–410.
   PubMedGoogle Scholar
• Tran B, Cohen MS. The discovery and development of binimetinib for the treatment of melanoma. Expert Opin Drug Discov. 2020 Jul;15(7):745–754.
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750–2760.
   PubMed Web of Science ®Google Scholar
• Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018 Mar 28;8:86.
   Google Scholar
• Sondak VK, Smalley KSM, Kudchadkar R, et al. Nature reviews drug discovery. [cited 2021 Apr 21]. Available from: https://www.nature.com/arti cles/nrd3463 (2011).
   Google Scholar
• Liu Y, Zheng P. How does an anti-CTLA-4 antibody promote cancer immunity? Trends Immunol. 2018;39(12):953–956.
   PubMed Web of Science ®Google Scholar
• Rausch MP, Hastings KT. Immune checkpoint inhibitors in the treatment of melanoma: from basic science to clinical application.  In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 9. p. 121–142.
   Google Scholar
• Petrova V, Arkhypov I, Weber R, et al. Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. Int J Mol Sci. 2020 Apr; 21(7): 2367.
   Web of Science ®Google Scholar
• Baumgartner J, Wilson C, Palmer B, et al. Melanoma induces immunosuppression by up-regulating FOXP3+ Regulatory T cells. J Surg Res. 2007;141(1):72–77.
   PubMed Web of Science ®Google Scholar
• Ward-Hartstonge KA, Kemp RA. Regulatory T-cell heterogeneity and the cancer immune response. Clin Transl Immunol. 2017;6(9):e154.
   PubMedGoogle Scholar
• Sharma A, Subudhi SK, Blando J, et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3 + regulatory T Cells (Tregs) in human cancers. Clin Cancer Res. 2019;25(4):1233–1238.
   PubMed Web of Science ®Google Scholar
• Chatterjee MS, Elassaiss-Schaap J, Lindauer A, et al. Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):29–39.
   PubMedGoogle Scholar
• Freeman GJ, Long AJ, Iwai Y. Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):7.
   Web of Science ®Google Scholar
• Fessas P, Lee H, Ikemizu S, et al. Seminars in Oncology. Seminars in Oncology. 2017;44(2):136–140.
   PubMed Web of Science ®Google Scholar
• Assessment report OPDIVO International non-proprietary name: nivolumab. London: European Medicines Agency. 2015
   Google Scholar
• EMA Assessment report Keytruda International non-proprietary name: pembrolizumab. 2015
   Google Scholar
• Renner A, Burotto M, Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Glob Oncol. 2019;5:1–5.
   PubMed Web of Science ®Google Scholar
• Munhoz RR, Postow MA. Clinical development of PD-1 in advanced melanoma. Cancer J (United States). 2018;24:7–14.
   Web of Science ®Google Scholar
• Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–128.
   PubMed Web of Science ®Google Scholar
• Das S and Johnson D.B., Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. Journal for Immunotherapy of Cancer 2019 (7) 306; 1-11. [cited 2021 Apr 21]. Available from: https://doi.org/10.1186/s40425-019-0805-8.
   Google Scholar
• Quach HT, Dewan AK, Davis EJ, et al. Association of anti–programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol. 2019;5(6):906–908.
   PubMed Web of Science ®Google Scholar
• Li L, Li G, Rao B, et al. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. Sci Rep. 2020;10(1):15567.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: pd-1/Pd-L1 blockade in melanoma. Clin Ther. 2015;37(4):764–782.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Gunturi A, Perritt J, et al. A retrospective analysis of high-dose interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016;4:52.
   PubMedGoogle Scholar
• Long G, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). Presented at: AACR annual meeting 2021; April 10-15, 2021; Virtual. Abstract CT004.
   Google Scholar
• Hodi F, Chiarion-Sileni V, Gonzalez R, et al., Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19(11): 1480–1492. 2018.
   PubMed Web of Science ®Google Scholar
• Postow M Toxicities associated with checkpoint inhibitor immunotherapy. UpToDate March 2021. [cited 2021 Apr 21]. Available from: https://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy.
   Google Scholar
• Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6(4):519–527.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018 Aug 23;379(8):722–730.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19(5):672–681.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–983.
   PubMed Web of Science ®Google Scholar
• Blank C, Rozeman EA, Menzies AM, et al. Annals of Oncology. 2018; Vol. 29. Supplement 8, viii734.
   Google Scholar
• Herrsher H, Robert C. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. Curr Opin Oncol. 2020;32(2):106–113.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017 Jun 1;123(11):1904–1911.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results from the EORTC 18071 double-blind phase 3 randomized trial. J Clin Oncol. 2019;37(15_suppl):2512–12512.
   Web of Science ®Google Scholar
• Eggermont AM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835.
   PubMed Web of Science ®Google Scholar
• Weber JS, Del Vecchio M, Mandala M. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 study. Ann Oncol. 2019;30(suppl_5):v533–v563.
   Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–376.
   PubMed Web of Science ®Google Scholar
• Poulet FM, Wolf JJ, Herzyk DJ, et al. An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors. Birth Defects Res B Dev Reprod Toxicol. 2016;107(2):108–119.).
   PubMedGoogle Scholar
• Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020 Jan 31;367(6477):eaax0182.
   PubMed Web of Science ®Google Scholar
• Boulva K, Apte S, Yu A, et al. Contemporary neoadjuvant therapies for high-risk melanoma: a systematic review. Cancers (Basel). 2021 Apr;13(8):1905. Published online 2021 Apr 15.
   PubMed Web of Science ®Google Scholar
• Herndon TM, Demko SG, Jiang X, et al. U.S. food and drug administration approval: peginterferon‐alfa‐2b for the adjuvant treatment of patients with melanoma. Oncologist. 2012;17(10):1323–1328.
   PubMed Web of Science ®Google Scholar
• Leonardi GC, Candido S, Falzone L, et al. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol. 2020;57(3):609–618.
   PubMed Web of Science ®Google Scholar
• Conry RM, Westbrook B, McKee S, et al.Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14(4):839–846.
   Google Scholar
• BL L, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003 Feb;10(4):292–303.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS. Talimogene laherparepvec for the treatment of advanced melanoma. Clin Cancer Res. 2016;22(13):3127–3131.
   PubMed Web of Science ®Google Scholar
• Testori A, Ribero S, Bataille V. Diagnosis and treatment of in-transit melanoma metastases. Eur J Surg Oncol. 2017;43(3):544–560.
   PubMed Web of Science ®Google Scholar
• Turza K, Dengel LT, Harris RC, et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol. 2010;37(1):94–98.
   PubMed Web of Science ®Google Scholar
• Gabriel E, Skitzki J. The role of regional therapies for in-transit melanoma in the era of improved systemic options. Cancers (Basel). 2015;7(3):1154–1177.
   PubMed Web of Science ®Google Scholar
• Weitman ES, Zager JS. Regional therapies for locoregionally advanced and unresectable melanoma. Clin Exp Metastasis. 2018;35(5–6):495–502.
   PubMed Web of Science ®Google Scholar
• Wang T, Osborne N, Rechtenwald J, et al. Improved durable responses regardless of age following cytoreduction and “no-tourniquet” hyperthermic isolated limb chemotherapy for in transit melanoma of the extremity. Am J Surg. 2019;218(6):1114–1121.
   PubMed Web of Science ®Google Scholar
• Walpole SC, Prieto-Merino D, Edwards P, et al. The weight of nations: an estimation of adult human biomass. BMC Public Health. 2012;12:439.
   PubMedGoogle Scholar
• [cited 2020 Dec 1]. Available from: https://reference.medscape.com/drug/referenced march 31 2021
   Google Scholar
• Vemurafenib: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/vemurafenib-drug-information (2020).
   Google Scholar
• Dabrafenib: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/dabrafenib-drug-information (2020).
   Google Scholar
• Encorafenib: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/encorafenib-drug-information (2020).
   Google Scholar
• Trametinib: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/trametinib-drug-information (2020).
   Google Scholar
• Cobimetinib: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/cobimetinib-drug-information (2020).
   Google Scholar
• Binimetinib: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/binimetinib-drug-information (2020).
   Google Scholar
• Ipilimumab: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/ipilimumab-drug-information (2020).
   Google Scholar
• Nivolumab: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/nivolumab-drug-information (2020).
   Google Scholar
• Pembrolizumab: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/pembrolizumab-drug-information (2020).
   Google Scholar
• Aldeslukin: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/aldesleukin-drug-information (2020).
   Google Scholar
• Interferon Alfa: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/interferon-alfa-2b-drug-information (2020).
   Google Scholar
• Peg Interferon: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2b-drug-information (2020).
   Google Scholar
• Talimogene laherparepvec: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/talimogene-laherparepvec-drug-information (2020).
   Google Scholar
• Dacarbazine: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/dacarbazine-drug-information (2020).
   Google Scholar
• Temolozomide: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/temolozomide-drug-information (2020).
   Google Scholar
• Paclitaxel: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/paclitaxel-conventional-drug-information (2020).
   Google Scholar
• Nanoparticle Albumin Bound Paclitaxel: Drug Information. Lexicomp https://www.uptodate.com/contents/nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information (2020).
   Google Scholar
• Carboplatin: Drug Information. Lexicomp [cited 2020 Dec 1]. Available from: https://www.uptodate.com/contents/carboplatin-drug-information (2020).
   Google Scholar
• Sharma M, Khong H, Faak F, et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 5;312(17):1744–1753.
   PubMed Web of Science ®Google Scholar
• Haymaker C, Johnson DH, Murthy R, et al. Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021:1–32. Published online first. doi: 10.1158/2159-8290.CD-20-1546.
   Google Scholar
• Rothermel LD, Zager JS. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next? Expert Opin Biol Ther. 2018 Dec;18(12):1199–1207.
   PubMed Web of Science ®Google Scholar
• Rohaan MW, van den Berg JH, Kvistborg P, et al. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer. 2018 Oct 3;6(1):102.
   PubMed Web of Science ®Google Scholar
• Corrie PG, Marshall A, Nathan PD, et al. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol. 2019 Dec 1;30(12):2013–2014.
   PubMed Web of Science ®Google Scholar
• Desai BM, Villanueva J, Nguyen TT, et al. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One. 2013;83:e59588.
   PubMed Web of Science ®Google Scholar
• Hardin MO, Vreeland TJ, Clifton GT, et al. Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. Immunotherapy. 2018 Apr;10(5):373–382.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011 May 15;117(10):2202–2208.
   PubMed Web of Science ®Google Scholar
• Chan AS, Jonas AB, Qiu X, et al. Imprime PGG-mediated anti-cancer immune activation requires immune complex formation. PLoS One. 2016 Nov 3;11(11):e0165909.
   PubMed Web of Science ®Google Scholar
• Rubio-Pérez J, Hernández R, Hernández T, et al. Dostarlimab for the treatment of endometrium cancer and other solid tumors. Drugs Today (Barc). 2021 Mar;57(3):187–197.
   PubMed Web of Science ®Google Scholar
• Maximova N, Maestro A, Zanon D, et al. Rapid recovery of postnivolumab vemurafenib-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome after tocilizumab and infliximab administration. J Immunother Cancer. 2020 Feb;8(1):e000388.
   PubMed Web of Science ®Google Scholar
• Angela Y, Haferkamp S, Weishaupt C, et al. Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases. Cancer Immunol Immunother. 2019 Jul;68(7):1187–1194.
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Eroglu Z, Khushalani NI, et al. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). Melanoma Res. 2021 Apr 1;31(2):162–172.
   PubMed Web of Science ®Google Scholar
• Read TA, Smith A, Thomas J, et al. Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study. J Surg Oncol. 2018 Mar;117(4):579–587.
   PubMed Web of Science ®Google Scholar
• Hornig E, Heppt MV, Graf SA, et al. Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside. Exp Dermatol. 2016 Nov;25(11):831–838.
   PubMed Web of Science ®Google Scholar
• Lee EF, Harris TJ, Tran S, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019 Apr 24;10(5):342.
   PubMedGoogle Scholar